New drug offers promise for hep C cure

Merck and Co. Thursday presented new data from an ongoing Phase 2 clinical trial to evaluate the safety and efficacy of a once-a-day pill for the treatment of chronic hepatitis C. The company reports a 12-week regimen of the drug therapy — a compound of MK-5172 and MK-8742v — has a cure rate of 98 percent.

Read the source article at CBS News

About the Author

Leave a Reply